Frontiers in medicineOct 13, 2026

Different eye safety effects of glucagon-like peptide-1 receptor drugs based on their chemical differences

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 14, 2026

Abstract

Semaglutide is linked to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) and early deterioration of diabetic retinopathy during rapid glycemic correction.

Shorter-acting GLP-1 receptor agonists like liraglutide and exenatide show much weaker associations with ocular safety issues.
Differences in ocular safety profiles may arise from biased agonism and receptor trafficking at the molecular level.
Cell-type-specific signaling environments could influence how GLP-1 receptor agonists affect ocular health.
A proposed hemodynamic mechanism suggests that GLP-1 receptor agonists may alter intracranial pressure, impacting ocular outcomes.
The interplay between receptor occupancy, signaling, and anatomical vulnerabilities may contribute to the ocular risks associated with these drugs.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of type 2 diabetes and obesity, yet their ocular safety profile remains contested. The longer-acting semaglutide has been repeatedly linked to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) and, in situations of rapid glycemic correction, to early deterioration of diabetic retinopathy, while shorter-acting drugs such as liraglutide and exenatide show much weaker signals. This review explores the pharmacological underpinnings of this difference by combining three lines of evidence: biased agonism and trafficking at the receptor level, cell-type-specific signaling microenvironments, and a recently proposed hemodynamic mechanism based on GLP-1RA-mediated changes in intracranial pressure. The ocular liabilities of GLP-1RAs may be influenced by a multifactorial interplay between ligand-dictated receptor occupancy profiles, cell-type-specific signaling milieu, and individual anatomical vulnerabilities. This model makes testable predictions and has implications for drug choice, risk stratified monitoring, and the development of future agonists with enhanced ocular safety. Key areas for future research include head-to-head comparisons of different GLP-1RAs' signaling in specific ocular cell types and the risk-benefit equation in non-diabetic individuals using these drugs for weight loss.

Full Text

Full text is available at the source.

View Full Text ↗

Different eye safety effects of glucagon-like peptide-1 receptor drugs based on their chemical differences

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief